Increased lymphoma risk in patients with systemic manifestations of Sjögren’s disease: a population-based study
Clinical Scorecard: Elevated Risk of Lymphoma in Patients Exhibiting Systemic Symptoms of Sjögren’s Disease: A Population-Based Analysis
At a Glance
Category Detail
Condition Key Mechanisms T and B lymphocytic infiltration of exocrine glands, systemic cytokine production. Target Population Care Setting
Key Highlights
53% of patients had a glandular phenotype; 47% had a systemic phenotype. Systemic involvement associated with higher ESSDAI scores (13.9 vs. 4.0; p < 0.001). Lymphoma occurred in 5% of patients, predominantly in those with systemic involvement (10% vs. 1%; p = 0.001). Immunosuppressive therapy was more commonly used in patients with systemic involvement. Sicca symptoms were highly prevalent: xerophthalmia (89%), xerostomia (84%). Guideline-Based Recommendations
Diagnosis
Use 2016 ACR/EULAR criteria for classification of pSjD. Consider SGUS as an alternative minor criterion. Management
Close follow-up of systemic pSjD phenotype for early diagnosis of lymphoma. Monitoring & Follow-up
Assess systemic disease activity using the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). Risks
Increased risk of lymphoma, particularly non-Hodgkin lymphoma, in patients with systemic involvement. Patient & Prescribing Data
Adult patients with primary Sjögren’s disease without other systemic autoimmune diseases.
Immunosuppressive therapy is more common in patients with systemic involvement.
Clinical Best Practices
Stratify patients based on glandular vs. systemic phenotypes. Incorporate SGUS findings into diagnostic work-up. Related Resources & Content
